BSE Live
Apr 20, 16:01Prev. Close
29.75
Open Price
29.24
Bid Price (Qty.)
29.20 (407)
Offer Price (Qty.)
29.24 (100)
NSE Live
Apr 09, 15:56Prev. Close
29.89
Open Price
31.67
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
31.97 (1)
| Cash Flow of Mangalam Drugs & Organics (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 4.99 | -11.06 | 2.21 | 27.73 | 39.52 | |
| Net CashFlow From Operating Activities | 42.76 | 12.17 | 39.52 | 25.71 | 27.55 | |
| Net Cash Used In Investing Activities | -19.47 | -17.91 | -22.17 | -27.33 | -31.29 | |
| Net Cash Used From Financing Activities | -21.71 | 5.70 | -16.62 | 2.98 | 2.70 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 1.57 | -0.04 | 0.73 | 1.36 | -1.04 | |
| Cash And Cash Equivalents Begin of Year | 1.00 | 1.04 | 1.95 | 0.58 | 1.63 | |
| Cash And Cash Equivalents End Of Year | 2.57 | 1.00 | 2.68 | 1.95 | 0.59 |
20.01.2026
Mangalam Drugs Consolidated December 2025 Net Sales at Rs 58.49 crore, down 34.07% Y-o-Y
20.01.2026
Mangalam Drugs Standalone December 2025 Net Sales at Rs 58.49 crore, down 34.07% Y-o-Y
25.11.2025
Mangalam Drugs Consolidated September 2025 Net Sales at Rs 49.54 crore, down 38.03% Y-o-Y
24.11.2025
Mangalam Drugs Standalone September 2025 Net Sales at Rs 49.54 crore, down 38.03% Y-o-Y
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth